| Title |
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
|
|---|---|
| Published in |
Investigational New Drugs, August 2018
|
| DOI | 10.1007/s10637-018-0648-z |
| Pubmed ID | |
| Authors |
Ciara M. Kelly, Alexander N. Shoushtari, Li-Xuan Qin, Sandra P. D’Angelo, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Chloe Mcfadyen, Ana Sjoberg, Samuel Singer, Ronald P. DeMatteo, Sinchun Hwang, M. H. Heinemann, Jasmine H. Francis, Cristina R. Antonescu, Ping Chi, William D. Tap |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 13% |
| Researcher | 7 | 13% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Other | 10 | 19% |
| Unknown | 18 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Agricultural and Biological Sciences | 4 | 8% |
| Psychology | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 20 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2019.
All research outputs
#3,611,767
of 23,100,534 outputs
Outputs from Investigational New Drugs
#121
of 1,175 outputs
Outputs of similar age
#69,702
of 330,840 outputs
Outputs of similar age from Investigational New Drugs
#5
of 18 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,175 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.